A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection

Area of Science:

• Biomedical Engineering
• Clinical Diagnostics
• Analytical Chemistry

Background:

• Global need for rapid, cost-effective diagnostic tools at the point-of-care.
• Late cancer diagnosis leads to increased treatment costs and reduced life expectancy.
• Prostate cancer screening is limited by the lack of a reliable, accessible test.

Purpose of the Study:

• To develop and validate a microelectronic platform for point-of-care metabolite biomarker measurement.
• To utilize the platform for the detection of prostate cancer.
• To assess the platform's performance in a preliminary clinical study.

Main Methods:

• Development of a microelectronic platform with photodetectors and microfluidic channels.
• Multiplexed colorimetric assays for 4 plasma metabolites (l-amino acids, glutamate, choline, sarcosine).
• Application of a cross-validated random forest algorithm to analyze metabolite data.

Main Results:

• The platform completed a 4-metabolite assay in under 2 minutes from a single drop of plasma.
• Demonstrated 94% sensitivity and 70% specificity for prostate cancer detection.
• Achieved an area under the curve (AUC) of 0.78 in a preliminary clinical study.

Conclusions:

• The developed microelectronic platform enables rapid, low-cost point-of-care testing.
• This technology has the potential to significantly improve early disease diagnosis, starting with prostate cancer.
• The platform's adaptability for various assay panels suggests a revolutionary impact on diagnostic testing.